View as an RSS Feed
CorMedix: Making Progress In Both EU Commercial And U.S. Regulatory Fronts
- Recent capital raise removes liquidity risk.
- Last week's board of directors additions strengthen management depth.
- Sales commence in EU as of Q4 2013.
- U.S. trial may be Fast-Tracked.
- Neutrolin may be eligible for GAIN Act status.
- CorMedix: An Interesting Play In The Catheter Care Space
- Ziopharm: A Short Squeeze In The Making?
- Ziopharm: Small Molecules Meet Next-Generation Synthetic Biology
- Ziopharm Oncology: Place Your Bets
- Ziopharm: The Money's in the Bank, So What's Next?
- Ziopharm Oncology: Step by Step
- Ziopharm Oncology: Deal or Dilution?
- Will Big Pharma Misplay Their Advantage?
- Ziopharm Oncology: Thinking Small